Immunorho (Human Anti-D Immunoglobulin)

Immunorho, an anti‑D immunoglobulin, is used in the Rh‑alloimmunization pathway to prevent maternal sensitization.

• Prevention of Rh alloimmunization in Rh‑negative pregnant women: provides passive anti‑D antibodies to neutralize fetal RhD‑positive cells, reducing risk of hemolytic disease in the newborn.
• Prophylaxis after delivery of an Rh‑positive infant to an Rh‑negative mother: administered within 72 hours to prevent sensitization.
• Prophylaxis after miscarriage or termination in Rh‑negative women: given to avoid immune response to fetal red cells.
• Prophylaxis after invasive prenatal procedures (amniocentesis, chorionic villus sampling) in Rh‑negative women: reduces chance of alloimmunization following fetal‑maternal hemorrhage.

• Human Anti‑D Immunoglobulin consists of purified IgG antibodies that specifically bind the RhD antigen on erythrocytes. After intramuscular injection, the antibodies circulate and rapidly attach to any fetal RhD‑positive red cells that enter the maternal bloodstream, facilitating their clearance and preventing the maternal immune system from recognizing and producing its own anti‑RhD antibodies. This passive immunization blocks the sensitization cascade that leads to hemolytic disease of the fetus and newborn.

The following adverse reactions have been reported with intramuscular Human Anti‑D Immunoglobulin.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema or edema.
• Low‑grade fever: transient temperature rise within 24 hours.
• Headache: mild headache not requiring intervention.
• Nausea: occasional mild nausea post‑administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with respiratory distress or hypotension.
• Serum sickness: fever, rash, arthralgia occurring days after injection.
• Hemolysis: rapid destruction of red blood cells leading to anemia.
• Thrombocytopenia: marked drop in platelet count.
• Renal impairment: acute kidney injury in rare cases.

When using Immunorho, several precautions should be observed to ensure safety and efficacy.

• Rh status verification: confirm the patient is Rh‑negative before administration.
• Allergy assessment: screen for IgA deficiency or previous severe reactions to blood products.
• Pregnancy monitoring: use under obstetric supervision and monitor fetal well‑being.
• Concomitant blood products: avoid simultaneous infusion of other immunoglobulins without proper spacing.
• Volume overload: assess cardiac status in patients at risk of fluid overload.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Anti‑D Immunoglobulin may interact with certain agents; awareness of these interactions helps manage patient therapy.

Major Interactions (Avoid)

• Live vaccines: administration may reduce vaccine efficacy; defer vaccination for 3 months after anti‑D.
• IgA‑deficient blood products: risk of severe allergic reaction; avoid co‑administration.

Moderate Interactions (Monitor Closely)

• Other immunoglobulin preparations: increased risk of volume overload and hypersensitivity; monitor infusion rates.
• Immunosuppressive therapy: may alter immune response to anti‑D; observe for reduced prophylactic effect.
• Anticoagulants: minor increase in bleeding risk due to injection site bruising; monitor coagulation parameters.